NRx Pharmaceuticals announced that it entered into a definitive purchase agreement subject to standard closing conditions with an accredited investor to purchase approximately 2.7M shares of unregistered common stock at 38c per share, along with an equal number warrants to purchase common stock at 40c per share; the term on these warrants is five years. NRx Pharmaceuticals received approximately $1M in cash from an existing investor.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NRXP:
- NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share
- NRx Pharmaceuticals announces common stock offering, no amount given
- NRx Pharmaceuticals launches HOPE Therapeutics at BIO Conference
- NRX Pharmaceuticals Amends Repayment Terms with Streeterville Capital
- NRx Pharmaceuticals Secures Funding and Expands Alvogen Partnership
